While single-arm studies showed ORR of 62–73% (47–50% CR) among TP53-mutated, HMA-naïve patients with MDS and CMML, the manufacturer has recently announced that the randomized phase III trial failed to reach its primary endpoint of OS but the publication of trial results needs to be awaited to evaluate if there are any subgroups who might benefit from APR-246 + AZA [127,128]. The gene discussed is TP53; the disease is chronic myelomonocytic leukemia.